Messenger RNA vaccines were highly effective at preventing people from suffering the most severe outcomes from COVID-19 even as infectious new coronavirus variants spread, a U.S. study found.

Receiving two or three doses of a vaccine made by either Moderna Inc. or partners Pfizer Inc. and BioNTech SE led to a 90% reduction in the risk of needing to be put on a ventilator or death because of COVID-19, according to a study published by the Centers for Disease Control and Prevention on Friday.

Unable to view this article?

This could be due to a conflict with your ad-blocking or security software.

Please add japantimes.co.jp and piano.io to your list of allowed sites.

If this does not resolve the issue or you are unable to add the domains to your allowlist, please see out this support page.

We humbly apologize for the inconvenience.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.